Megestrol Acetate Patent Expiration
Megestrol Acetate is Used for treating anorexia, cachexia, or unexplained significant weight loss in AIDS patients. It was first introduced by Bristol Myers Squibb
Megestrol Acetate Patents
Given below is the list of patents protecting Megestrol Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Megace Es | US7101576 | Nanoparticulate megestrol formulations |
Apr 22, 2024
(Expired) | Endo Operations |
| Megace Es | US9040088 | Nanoparticulate megestrol formulations |
Apr 22, 2024
(Expired) | Endo Operations |
| Megace Es | US9101540 | Nanoparticulate megestrol formulations |
Apr 22, 2024
(Expired) | Endo Operations |
| Megace Es | US9101549 | Nanoparticulate megestrol formulations |
Apr 22, 2024
(Expired) | Endo Operations |
| Megace Es | US9107827 | Nanoparticulate megestrol formulations |
Apr 22, 2024
(Expired) | Endo Operations |
| Megace Es | US6592903 | Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
Sep 21, 2020
(Expired) | Endo Operations |
About Veterinary Megestrol Acetate
Megestrol Acetate is used in a drug marketed by 1 company: Intervet Inc.
Other drugs containing Megestrol Acetate are: Ovaban tablets 20 mg, ovaban tablets 5 mg .
Megestrol Acetate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Megestrol Acetate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
